CRISPR Therapeutics AG (CRSP) Liabilities and Shareholders Equity (2015 - 2026)

CRISPR Therapeutics AG has disclosed Liabilities and Shareholders Equity across 12 years of filings, most recently posting $2.7 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 30.6% year-over-year to $2.7 billion; the TTM figure through Jun 2026 stood at $9.9 billion (up 13.72% YoY), while the FY2025 annual figure was $2.3 billion, up 1.04% from the prior year.
• Liabilities and Shareholders Equity came in at $2.7 billion for Q2 2026 at CRISPR Therapeutics AG, down from $2.7 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.7 billion in Q1 2026 to a low of $2.0 billion in Q2 2025.
• Average Liabilities and Shareholders Equity over 5 years is $2.3 billion, with a median of $2.3 billion recorded in 2024.
• The largest YoY upside for Liabilities and Shareholders Equity was 33.11% in 2022 against a maximum downside of 18.49% in 2022.
• Over 5 years, Liabilities and Shareholders Equity stood at $2.2 billion in 2022, then dropped by 0.6% to $2.2 billion in 2023, then advanced by 0.56% to $2.2 billion in 2024, then grew by 1.04% to $2.3 billion in 2025, then climbed by 17.02% to $2.7 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $2.7 billion in Q2 2026, $2.7 billion in Q1 2026, and $2.3 billion in Q4 2025.